Press Releases

February 9, 2017

Ovid Therapeutics and NeuroPointDX Announce Collaboration to Identify Biomarkers for Angelman Syndrome
READ MORE

February 9, 2017

Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome
READ MORE

January 19, 2017

Ovid Therapeutics Names Jacqueline A. French, M.D. to Scientific Advisory Board
READ MORE

January 18, 2017

Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies
READ MORE

November 29, 2016

Ovid Therapeutics to Participate in Two Upcoming Investor Conferences
READ MORE

September 8, 2016

Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for the Treatment of Patients with Angelman Syndrome
READ MORE

September 1, 2016

Ovid Therapeutics Announces Participation in Two Upcoming Investors Conferences
READ MORE

April 13, 2016

Ovid Therapeutics Expands Leadership Team and Scientific Advisory Board
READ MORE

January 21, 2016

Ovid Therapeutics Announces Election of Industry Leader Douglas E. Williams, Ph.D., to Its Board of Directors
READ MORE

November 23, 2015

Ovid Therapeutics Announces Election of Bart Friedman to Its Board of Directors
READ MORE

October 15, 2015

Ovid Therapeutics Announces Appointment of Dr. Anna Kazanchyan to Senior Vice President, Business Development
READ MORE

October 8, 2015

Ovid Therapeutics Appoints Dr. Jerome B. Zeldis to Its Scientific Advisory Board
READ MORE

September 30, 2015

Ovid Therapeutics Appoints Dr. Karen Bernstein to its Board of Directors
READ MORE

September 8, 2015

Ovid Therapeutics to Participate in Citi’s 10th Annual Biotech Conference
READ MORE

August 11, 2015

Ovid Therapeutics Completes Oversubscribed $75 Million Series B Financing
READ MORE

June 4, 2015

Ovid Therapeutics Announces Appointment of Highly-Ranked Biotechnology Research Analyst Dr. Yaron Werber as Chief Financial Officer
READ MORE

May 29, 2015

Ovid Therapeutics to Present at Jefferies 2015 Global Healthcare Conference
READ MORE

April 16, 2015

Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol
READ MORE

April 16, 2015

Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer
READ MORE

April 16, 2015

Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer
READ MORE

Join Our Mailing List

Sign up for our distribution list to be notified of future press releases.

Event Schedule

December 15, 2016

Dr. Jeremy M. Levin to present at Xconomy’s New York Life Sciences 2021
MORE INFO

December 14, 2016

Dr. Yaron Werber, Chief Business & Financial Officer to present at the BMO Capital Markets: Prescription for Success Healthcare Conference
MORE INFO

December 7, 2016

Dr. Jeremy M. Levin, Chief Executive Officer & Dr. Yaron Werber, Chief Business & Financial Officer to attend Citi’s 2016 Global Healthcare Conference
MORE INFO

December 2, 2016

Ovid Therapeutics to participate at the FAST Global Summit on Angelman Syndrome and Gala 2016
MORE INFO